MENLO PARK, Calif.--(BUSINESS WIRE)--Nov. 18, 2009--
Depomed, Inc. (NASDAQ:DEPO) announced today that William Callahan has
been promoted to vice president, Operations. Mr. Callahan joined Depomed
in 2002 and most recently held the position of senior director,
Operations.
Mr. Callahan has spent most of his more than 20-year career in emerging
growth companies, establishing and growing operations groups, and
participating in the launch of numerous new products. Prior to Depomed,
Mr. Callahan held director of operations positions at Avocet Medical,
Cygnus Therapeutics, Applied Biosystems and Johnson & Johnson Lifescan.
He received a B.S. degree in Chemistry from San Francisco State
University.
“I would like to congratulate Bill on his promotion on behalf of the
rest of the company and the Board of Directors. Bill is an excellent
manager who has successfully and efficiently ensured seamless product
supply for our clinical trials and commercial products. This key
function of his department has allowed Depomed to achieve its success to
date such as growing GLUMETZA to a current annual run rate of close to
$50 million in sales, scaling up the manufacturing of DM-1796 so that we
can support the future commercial success of DM-1796 with our partner
Solvay, and continuing the manufacturing of Serada product supply,” said
Carl Pelzel, Depomed’s president and chief executive officer.
About Depomed
Depomed, Inc. is a specialty pharmaceutical company with one product
candidate through Phase 3 clinical development, another in Phase 3
clinical development, two approved products on the market and other
product candidates in its early stage pipeline. Product candidate
DM-1796 has completed Phase 3 clinical development and has been licensed
to Solvay Pharmaceuticals. A New Drug Applications for DM-1796 is
expected to be filed with the FDA in the first quarter of 2010. Product
candidate SeradaTM is in Phase 3 clinical development for
menopausal hot flashes. GLUMETZA(R) (metformin hydrochloride
extended release tablets) is approved for use in adults with type 2
diabetes and promoted by Santarus, Inc. in the United States. Depomed
formulates its products and product candidates with its proven,
proprietary Acuform(R) drug delivery technology, which is
designed to improve existing oral medications, allowing for extended,
controlled release of medications to the upper gastrointestinal tract.
Benefits of Acuform-enhanced pharmaceuticals include the convenience of
once-daily administration, improved treatment tolerability and enhanced
compliance and efficacy. Additional information about Depomed may be
found on its website, www.depomed.com.
“Safe Harbor” Statement under the Private Securities Litigation
Reform Act of 1995.
The statements that are not historical facts contained in this
release are forward-looking statements that involve risks and
uncertainties including, but not limited to, those related to our
manufacturing capabilities; our research and development efforts,
including pre-clinical and clinical testing; regulation by the FDA and
other government agencies; the timing of regulatory applications and
product launches; and other risks detailed in the company’s Securities
and Exchange Commission filings, including the company’s Annual Report
on Form 10-K and most recent Quarterly Report on Form 10-Q. You are
cautioned not to place undue reliance on these forward-looking
statements which speak only as of the date hereof. The company
undertakes no obligation to publicly release the result of any revisions
to these forward-looking statements that may be made to reflect events
or circumstances after the date hereof or to reflect the occurrence of
unanticipated events.
Source: Depomed, Inc.
Depomed, Inc.
Sheilah Serradell, 650-462-5900
sserradell@depomed.com
